A new study from UCLA Health has uncovered how inflammation in brain blood vessels exacerbates damage in vascular dementia ...

A new study from UCLA Health has uncovered how inflammation in brain blood vessels exacerbates damage in vascular dementia ...

Multiple Sclerosis, the most common neurological disorder in young adults, with symptoms usually occurring between the ages of 20 and 40 years. The r ...

The brain isn’t the only place where MS lesions can develop — the disease can also attack the spinal cord, ... In relapsing-remitting MS, ... This leads to inflammation and scarring. [2] ...

Secondary endpoints included the number of new or enlarging T2-weighted lesions as measured by MRI scans of the brain at 4, 8 and 12 weeks, and the proportion of patients free from any new T1-Gd+ ...

Oral high‑dose cholecalciferol reduced disease activity in CIS and early relapsing‑remitting MS. These findings support further investigation, including pulse high‑dose vitamin D as an add ...

Positive Phase 2 Results of Orelabrutinib in Patients with Relapsing-Remitting Multiple Sclerosis. ... T1 brain lesions at Week 12 (based on Gd+ T1 lesions at Weeks 4, 8, and 12) ...

Relapsing-remitting MS People with all forms of MS can have lesions, but people with a common type of MS called relapsing-remitting MS generally have recurrent episodes of inflammatory demyelination.

Investigators in Australia concluded that choroid plexus enlargement is associated with the expansion of chronic lesions and neurodegeneration ... in patients with relapsing-remitting ...

Cerebellum damage is common in relapsing-remitting MS and progressive forms of MS. In fact, it occurs in about 4 out of 5 people with the disease. But there’s no way to predict how MS will ...

NEW YORK, April 30, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory ...

The plan with Sanofi is now to have phase 3 studies, not only in relapsing-remitting MS, ... we have almost a complete suppression of inflammation, no gad-positive lesions and almost no new T2 ...